Atossa Therapeutics (ATOS) Competitors $1.20 -0.08 (-6.25%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ATOS vs. EYEG, TTPH, PHAT, EXAI, ORIC, STOK, OCS, ANAB, TECX, and TRMLShould you be buying Atossa Therapeutics stock or one of its competitors? The main competitors of Atossa Therapeutics include AB Corporate Bond ETF (EYEG), Tetraphase Pharmaceuticals (TTPH), Phathom Pharmaceuticals (PHAT), Exscientia (EXAI), ORIC Pharmaceuticals (ORIC), Stoke Therapeutics (STOK), Oculis (OCS), AnaptysBio (ANAB), Tectonic Therapeutic (TECX), and Tourmaline Bio (TRML). These companies are all part of the "medical" sector. Atossa Therapeutics vs. AB Corporate Bond ETF Tetraphase Pharmaceuticals Phathom Pharmaceuticals Exscientia ORIC Pharmaceuticals Stoke Therapeutics Oculis AnaptysBio Tectonic Therapeutic Tourmaline Bio AB Corporate Bond ETF (NASDAQ:EYEG) and Atossa Therapeutics (NASDAQ:ATOS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends. Does the media prefer EYEG or ATOS? In the previous week, Atossa Therapeutics had 14 more articles in the media than AB Corporate Bond ETF. MarketBeat recorded 14 mentions for Atossa Therapeutics and 0 mentions for AB Corporate Bond ETF. Atossa Therapeutics' average media sentiment score of 0.51 beat AB Corporate Bond ETF's score of 0.00 indicating that Atossa Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment AB Corporate Bond ETF Neutral Atossa Therapeutics Positive Does the MarketBeat Community believe in EYEG or ATOS? AB Corporate Bond ETF received 202 more outperform votes than Atossa Therapeutics when rated by MarketBeat users. Likewise, 71.04% of users gave AB Corporate Bond ETF an outperform vote while only 64.93% of users gave Atossa Therapeutics an outperform vote. CompanyUnderperformOutperformAB Corporate Bond ETFOutperform Votes43971.04% Underperform Votes17928.96% Atossa TherapeuticsOutperform Votes23764.93% Underperform Votes12835.07% Do analysts rate EYEG or ATOS? Atossa Therapeutics has a consensus price target of $6.75, indicating a potential upside of 462.50%. Given Atossa Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Atossa Therapeutics is more favorable than AB Corporate Bond ETF.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AB Corporate Bond ETF 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Atossa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in EYEG or ATOS? 64.2% of AB Corporate Bond ETF shares are owned by institutional investors. Comparatively, 12.7% of Atossa Therapeutics shares are owned by institutional investors. 58.2% of AB Corporate Bond ETF shares are owned by company insiders. Comparatively, 7.6% of Atossa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, EYEG or ATOS? AB Corporate Bond ETF has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500. Comparatively, Atossa Therapeutics has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Is EYEG or ATOS more profitable? Atossa Therapeutics' return on equity of -35.74% beat AB Corporate Bond ETF's return on equity.Company Net Margins Return on Equity Return on Assets AB Corporate Bond ETFN/A -104.96% -60.03% Atossa Therapeutics N/A -35.74%-33.51% Which has preferable valuation and earnings, EYEG or ATOS? AB Corporate Bond ETF has higher revenue and earnings than Atossa Therapeutics. AB Corporate Bond ETF is trading at a lower price-to-earnings ratio than Atossa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAB Corporate Bond ETF$10K2,501.80-$8.09M-$1.68-21.27Atossa TherapeuticsN/AN/A-$30.09M-$0.22-5.45 SummaryAtossa Therapeutics beats AB Corporate Bond ETF on 10 of the 16 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATOS vs. The Competition Export to ExcelMetricAtossa TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$161.03M$6.48B$5.07B$8.89BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-5.454.4283.5712.93Price / SalesN/A375.031,220.3088.33Price / CashN/A52.5939.4636.25Price / Book2.0310.126.936.25Net Income-$30.09M$153.61M$119.12M$225.93M7 Day Performance-12.41%-2.00%-1.83%-1.32%1 Month Performance-17.24%-7.47%-3.64%0.60%1 Year Performance55.64%31.80%31.64%26.23% Atossa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATOSAtossa Therapeutics1.2137 of 5 stars$1.20-6.3%$6.75+462.5%+62.2%$161.03MN/A-5.458Analyst DowngradeAnalyst RevisionGap DownEYEGAB Corporate Bond ETFN/A$35.74-0.2%N/AN/A$25.02M$10,000.00-21.2714TTPHTetraphase PharmaceuticalsN/A$2.20flatN/A+0.0%$15.98M$7.38M-0.10119PHATPhathom Pharmaceuticals2.3252 of 5 stars$8.73-6.8%$22.50+157.7%+17.8%$640.70M$680,000.00-1.53110EXAIExscientia2.2551 of 5 stars$4.84flat$7.00+44.6%N/A$632.93M$25.60M0.00280News CoverageORICORIC Pharmaceuticals4.1915 of 5 stars$8.74-1.7%$18.29+109.2%+22.4%$627.34MN/A-4.8680Analyst RevisionSTOKStoke Therapeutics3.8396 of 5 stars$11.31-2.6%$20.83+84.2%+171.2%$614.95M$8.78M0.00100OCSOculis2.6784 of 5 stars$14.91-0.7%$29.20+95.8%+55.3%$608.37M$980,000.000.002ANABAnaptysBio2.4863 of 5 stars$20.31+1.7%$54.64+169.0%+40.0%$607.66M$17.16M-3.34100TECXTectonic Therapeutic3.5107 of 5 stars$44.03+7.8%$72.25+64.1%N/A$602.79MN/A0.00120Analyst ForecastGap UpTRMLTourmaline Bio1.8572 of 5 stars$24.00+2.1%$65.00+170.8%+36.0%$602.60MN/A0.0044 Related Companies and Tools Related Companies EYEG Alternatives TTPH Alternatives PHAT Alternatives EXAI Alternatives ORIC Alternatives STOK Alternatives OCS Alternatives ANAB Alternatives TECX Alternatives TRML Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATOS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
